Technical Intelligence & Insights
Explore our curated collection of technical analyses and commercial scale-up strategies specifically focused on catalytic hydrogenation. These insights are designed to support R&D and procurement teams in optimizing their supply chains.
Novel patent CN108623598A details improved Imipenem synthesis reducing impurities and enhancing crystallinity for reliable pharmaceutical intermediate supply chains.
Patent CN101921229B details a novel asymmetric catalytic hydrogenation route for L-Stepholidine. Discover cost-effective, scalable manufacturing solutions for high-purity pharmaceutical intermediates.
Discover a safer, high-yield synthesis for Edoxaban intermediates via Diels-Alder cyclization. Eliminate sodium azide risks and reduce manufacturing costs with our scalable process.
Patent CN104402878A details high-purity Imiquimod production. This report analyzes cost reduction and supply chain reliability for pharmaceutical intermediates manufacturing.
Novel catalytic dehydrogenation route for 2-indol-3-yl-quinolines offers high purity and scalable manufacturing for global pharmaceutical intermediates supply chains.
Novel route for (R)-2-(2,5-difluorophenyl)pyrrolidine avoids noble metals, offering cost-effective API manufacturing solutions.
Patent CN108409651B details a novel hydrogenation method converting chloroquinaldine waste into high-purity 8-hydroxy-2-methylquinoline, offering significant cost reduction and supply chain reliability.
Patent CN115286504B details asymmetric hydrogenation for brivaracetam intermediate. Delivers high purity and supply chain stability for global pharmaceutical manufacturing.
Patent CN115322106B details a novel high-selectivity synthesis route. Achieve cost reduction in pharmaceutical intermediate manufacturing with scalable, mild conditions.
Patent CN110724164B details novel pyridine-substituted spiro ligands enabling high TON hydrogenation. Ideal for API intermediates.
Patent CN109134351B details a novel synthesis of S-3-(4-aminophenyl)piperidine with >99% ee, offering cost-effective scalability for PARP inhibitor manufacturing.
Novel patent CN119263959B details cost-effective 1,2-cyclopentanedimethanol production. Enhances supply chain reliability and reduces manufacturing complexity for pharmaceutical intermediates.
Advanced catalytic synthesis for Eltrombopag Olamine reduces costs and improves supply chain reliability for global pharmaceutical intermediates manufacturing partners.
Patent CN102351726A reveals a high-yield baclofen intermediate synthesis using ultrafine potassium carbonate, eliminating toxic solvents and cryogenic conditions for cost-effective manufacturing.
Patent CN110724164B discloses novel 3-substituted spiro ligands achieving 99% ee. Enables cost-effective API intermediate manufacturing with high TON.
Novel synthesis of Danshensu Isopropyl Ester via Darzens epoxidation ensures high purity and yield. Reliable supply chain partner for cardiovascular drug intermediates.
Patent CN114014768A details a barium-free continuous flow synthesis for high-purity tranexamic acid, offering significant cost reduction in API manufacturing and enhanced supply chain safety.
Patent CN114920655A reveals a cost-effective nitration-fluorination-reduction route for high-purity 2-fluoro-3-trifluoromethylaniline, offering significant supply chain advantages.
Novel scalable route for tegoprazan key intermediate offering high purity ≥99% and simplified post-processing for reliable pharmaceutical supply chains.
Patent CN109678840B reveals normal pressure hydrogenation for high-purity pomalidomide. Reduces equipment costs and enhances supply chain reliability for pharmaceutical intermediates.